Latest Conference Content

A late-breaking poster presented at ASGCT 2025 described the enhanced central nervous system transduction and safety of the vector.

A pediatric patient with a rare genetic disorder safely received a personalized CRISPR therapy, marking the first known case of a personalized CRISPR-based medicine administered to a single patient.

Tevard's tRNA therapy appears to restore full-length dystrophin and motor function in a Duchenne muscular dystrophy model, showing promise for nonsense mutation treatments.

The poster presentations contain data highlighting the company’s role to date in developing non-replicating HSV-1 technology for use in neurology.

The company’s technology was used to create CAR-T cells that demonstrated the expression of complex CARs in a single DNA donor.

BioPharm International® spoke with Ryan Larson, PhD, SVP, Head of Research at Umoja BioPharma about how emerging modalities in oncology treatments, including cell therapies, are evolving.

The company has had abstracts accepted for three oral presentations and five posters.

The company hopes that its proprietary circVec technology platform will become a gold standard for nucleic acid and viral therapeutics.

BioPharm International® sat down with Noah Kopcho, field application scientist at Gyros Protein Technologies, to talk about the challenges in the production of AAV vectors.

BioPharm International® spoke with Lun Xin, associate director at WuXi Biologics, about how automation can accelerate and improve the formulation of high-concentration biologics.

BioPharm International® spoke with Lun Xin, associate director at WuXi Biologics, about high-concentration biologics and some of the biggest challenges associated with their formulation.

Among the new data the company plans to show in its presentations is the successful, repeated dosing of an mRNA-LNP in monkeys.

The company’s exhibitions will be focused in the areas of its pipeline, proprietary capsid engineering, and manufacturing.

At INTERPHEX 2025, the Pharmaceutical Technology® Group spoke with Joe Katakowski, director of Research at the RTW Foundation on how challenging it is to develop treatments for ultra-rare diseases.

Even with, or perhaps because of, the rapidity with which changes in United States policy are developing, many in the bio/pharmaceutical industry are taking a longer view.

As single use becomes more prevalent, end users are looking for more customization, and regulators are refining their rules, says Todd Andrews of CPC in an interview with Pharmaceutical Technology® Group.

Sitting down with the PharmTech Group at INTERPHEX 2025, Michael Franco, global sales director at PSG Biotech, discussed the recent advancements in pharmaceutical flow sensor technology.

Nicole Hunter, head of Global WMArchitect at WMFTS, sat with the PharmTech Group at INTERPHEX 2025 to discuss the industry initiative around single-use assembly components that was prompted by the supply disruptions caused by the COVID-19 pandemic.

At INTERPHEX 2025, the PharmTech Group spoke with Dave Loula, global product director, ITT Engineered Valves, about innovation in advanced sensing technologies that answer customers' need for reliable valve function.

Christopher Murphy, director of Global Business Development and Service Customer Support at Environmental Specialties, sat down with the PharmTech Group at INTERPHEX 2025 to discuss the design and critical role of walk-in chambers in the bio/pharmaceutical industry.

Speaking at INTERPHEX 2025, William Wainwright, business development manager at Iwata Label USA, discusses the practical benefits of functional labels in protecting parenteral drugs.

Officially launched at INTERPHEX 2025, the Omni ASCENT is a next-generation off-site manufactured vertical utility solution that offers optimized cleanroom flexibility and efficiency.

BioPure’s BioClamp connector has been upgraded and is now manufactured to be 13% lighter than the previous model, allowing users to achieve a 26% reduction in carbon dioxide emissions across the full lifecycle of a product.

The company said the Stratyx 250 is the first bioreactor of its kind to offer biotech companies a combination of automation, remote process control, and flexibility.

Sherwin-Williams will showcase its advanced coating systems, which are designed to ensure safety, sterility, and efficiency in pharmaceutical manufacturing environments.

PharmTech Group chatted with Markus Laubscher of Orbia during DCAT Week 2025, covering the topics of sustainability, regulatory hurdles, next-generation innovation, and the DCAT Week experience.

BioPharm International® spoke with Helen Baker, director of Formulation Design at Quotient Sciences to find out how drug development can be optimized to ensure a more secure supply chain.

The company is highlighting its commitment to next-generation glass manufacturing in efforts to strengthen the pharmaceutical supply chain.

Christine Mya-San, global account manager at Roquette Pharma Solutions, discusses the most significant pharma ingredients at play over the past year and looks ahead at ingredient innovation.

Russell Miller, vice-president of Global Sales & Marketing at Enzene, discusses how continuous bioprocessing is at the forefront of changing biologics manufacturing moving forward.